Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients


“Biosimilars” are equivalent versions of monoclonal antibodies that have previously been FDA approved to treat various diseases.  Because antibodies are more complicated than simple drugs like acetaminophen and aspirin, etc., these drugs are not chemically identical to the original drug.   The main advantage of biosimilars is the reduction in
Dr. Januario Castro and the other doctors at the University of California, San Diego Moores Cancer Center have pushed for and pioneered non-chemo approaches to treat chronic lymphocytic leukemia (CLL) for many years. At ASH 2015, he discussed his results with the one of the very first and longest-established